Predicting Injection Site Muscle Damage I: Evaluation of Immediate Release Parenteral Formulations in Animal Models
Tóm tắt
Purpose. The current animal model generally accepted by the pharmaceutical industry and the FDA for assessment of muscle damage following intramuscular injection (IM) is the rabbit lesion volume model (RbLV). However, this model is resource intensive. The goal of this study was to find a resource sparing alternative to the rabbit lesion model for assessing injection site toleration in IM formulation screening.
Methods. Short term animal model alternatives to RbLV for evaluating IM formulations were examined. In addition to RbLV, myeloperoxidase (MPO), p-nitrophenyl N-acetyl-β-glucosaminide (NAβG) and/or plasma creatine phosphokinase (CK) activities were determined in rabbits (Rb) and rats (Rt) after injection of formulations (digoxin, azithromycin and danofloxacin). The edema from these formulations 24 hr after subcutaneous injection into the rat footpad (RFE) was also determined.
Results. MPO and NAβG were not considered very useful as biochemical predictors of muscle damage for these formulations. Histology generally correlated with RbLV values. Compared to saline, RbLV was marked for all formulations within 1–3 days of injection. After day 3, lesions quickly resolved, and no significant differences were found. For these formulations, all CK animal models and RFE were generally predictive of RbLV. A formulation with RtCK > 1000 U/L or RbCK > 3000 U/L, was predicted to be poorly, tolerated.
Conclusions. Due to ease, number of animals, time and intrinsic mechanism, we concluded that for most formulations, 2 and 4 hr RtCK data alone should be reasonably predictive of muscle damage.
Tài liệu tham khảo
Svendsen, O: Studies of Tissue Injuries Caused by Intramuscular Injection of Drugs and Vehicles, Thesis, Royal Veterinary and Agricultural University, Copenhagen, 1988.
Gray, J. E.: In: Sustained and Controlled Release Delivery Systems, JR Robinson (ed.), Marcel Dekker, NY, 1978, pp. 351–410.
Gray, J. E.: Fund Appl Tox 1 290–292, 1981.
Surber C. and H. Sucker: Pharm Res 4:490–494, 1987.
Comereski C. R., P. D. Williams, C. L. Bregman and G. H. Hottendorf: Fund Appl Tox 6 335–338, 1986.
Anderson, K. E. and Damsgaard, T.: Acta med. scand. 199:317–319, 1976.
Meltzer H. Y., S. Mrozak, M. Boyer: Amer. J. Med. Sci. 259:42–48, 1970.
Steiness E., F. Rasmussen, O. Svendsen and P. Nielsen: Acta Pharmacol et Toxicol 42:357–364, 1978.
Svendsen O., F. Højelse and R. E. Bagdon: Acta Pharmacol et Toxicol 56:183–190, 1985.
Lefkowitz D. L., K. Mills, D. Morgan and S. S. Lefkowitz: Proc. Soc. Exp. Biol. Med. 199:204–210, 1992.
Pettipher E. R., B. Henderson, S. Moncada and G. A. Higgs: Br. J. Pharmacol. 95:169–76, 1988.
Szasz G., W. Gruber and E. Bernt: Clin. Chem. 22 650–656, 1976.
Brazeau G. A. and H.-L. Fung: Biochem J 257 619–621, 1989.
Miller M. J. S., H. Sadowska-Krowicka, S. Chotinaruemol, J. L. Kakkis and D. A. Clark: J. Pharmacol. Exp. Ther. 261 11–16, 1993.
Shintani S., M. Yamazaki, M. Nakamura and I. NakayamaL: Tax Appl Pharmacol 11 293–301, 1967.
Oshida S., K. Degawa, Y. Takahashi and S. Akaishi: Tnhoku J exp Med 127 301–316, 1979.
Steiness E., O. Svendsen and F. Rasmussen: Clin Pharmacol Ther 16 430–434, 1974.
Brazeau G. A. and H.-L. Fung: Pharm Res 6 167–170, 1989.
Brazeau, G. A. and H.-L. Fung: J Pharm Sci 79 393–397, 1990.
Svendsen, O.: Local muscle damage and oily vehicles: Acta pharmacol et. toxicol 52 298–304, 1983.
Brazeau, G., Gatlin, L. A., Jackson, M., Sutton, S. C., Gupta, P. K.: Symposium on The Evaluation of Pain, Irritation and Tissue Damage with Parenteral Formulations. AAPS Tenth Annual Meeting, Miami Beach, FL, 5–9 Nov., 1995.
Greenblatt J., D. W. Duhme, M. Penna, T. Greiner and H. Gold: N Eng. J Med 288 651–654, 1973.
Meltzer, H.: Biochem. Pharmacol. 20 1739–1748, 1971.
Wamock, D. G. and G. L. Ellman: Science 164 726, 1969.
Paget and H McG Scott: Brit J Pharmacol 12 427–433, 1957.
Brazeau, G. A., S. S. Watts and L. S. Mathews: J Parent Sci Tech, 46 25–30, 1992.